A.R.T. Advisors LLC Reduces Position in Catalyst Pharmaceuticals Inc (CPRX)

A.R.T. Advisors LLC decreased its holdings in Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) by 37.4% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 109,954 shares of the biopharmaceutical company’s stock after selling 65,610 shares during the quarter. A.R.T. Advisors LLC’s holdings in Catalyst Pharmaceuticals were worth $262,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Millennium Management LLC purchased a new position in shares of Catalyst Pharmaceuticals in the fourth quarter worth approximately $8,082,000. Tanaka Capital Management Inc. boosted its holdings in shares of Catalyst Pharmaceuticals by 6.4% in the fourth quarter. Tanaka Capital Management Inc. now owns 256,593 shares of the biopharmaceutical company’s stock worth $1,003,000 after buying an additional 15,515 shares during the last quarter. Mangrove Partners purchased a new position in shares of Catalyst Pharmaceuticals in the fourth quarter worth approximately $3,615,000. Geode Capital Management LLC boosted its holdings in shares of Catalyst Pharmaceuticals by 18.9% in the fourth quarter. Geode Capital Management LLC now owns 746,011 shares of the biopharmaceutical company’s stock worth $2,916,000 after buying an additional 118,799 shares during the last quarter. Finally, JBF Capital Inc. purchased a new position in shares of Catalyst Pharmaceuticals in the first quarter worth approximately $1,096,000. 53.33% of the stock is currently owned by institutional investors.

In related news, Director Donald A. Denkhaus bought 20,000 shares of the stock in a transaction dated Wednesday, May 30th. The shares were purchased at an average price of $3.75 per share, with a total value of $75,000.00. Following the completion of the acquisition, the director now owns 120,000 shares of the company’s stock, valued at $450,000. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. Insiders bought 29,000 shares of company stock worth $106,940 in the last three months. Insiders own 9.60% of the company’s stock.

Shares of Catalyst Pharmaceuticals opened at $3.29 on Friday, Marketbeat reports. Catalyst Pharmaceuticals Inc has a 1-year low of $2.09 and a 1-year high of $4.51. The company has a market cap of $337.54 million, a price-to-earnings ratio of -15.67 and a beta of 1.59.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last released its earnings results on Wednesday, May 9th. The biopharmaceutical company reported ($0.06) EPS for the quarter, hitting the consensus estimate of ($0.06). equities research analysts forecast that Catalyst Pharmaceuticals Inc will post -0.34 EPS for the current fiscal year.

Several equities analysts have weighed in on the stock. BidaskClub raised shares of Catalyst Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Wednesday, May 16th. ValuEngine raised shares of Catalyst Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Monday, May 14th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $6.00 price target on shares of Catalyst Pharmaceuticals in a report on Thursday, March 15th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $6.25.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases. Its product candidates include Firdapse, a proprietary form of amifampridine phosphate that has completed Phase III clinical trials for the treatment of patients with lambert-eaton myasthenic syndrome; is in Phase III clinical trial to treat congenital myasthenic syndromes; and is in Phase III clinical trial for the treatment of anti-MuSK antibody positive myasthenia gravis, as well as is in Phase II clinical trial for patients with spinal muscular atrophy type 3.

Want to see what other hedge funds are holding CPRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Catalyst Pharmaceuticals Inc (NASDAQ:CPRX).

Institutional Ownership by Quarter for Catalyst Pharmaceuticals (NASDAQ:CPRX)

Receive News & Ratings for Catalyst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply